EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 781 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns October 11, 2019 FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 April 6, 2022 EMA Recommends Granting a Marketing Authorisation for Elacestrant July 26, 2023 Load more HOT NEWS ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS) Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced... Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started Addressing the Challenges of Cancer Misinformation on Social Media
